CF PharmTech, Inc. (CF PharmTech) disclosed a repurchase of 144,600 H shares on 30 September 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices ranging between HKD 6.66 and HKD 6.99, with a volume-weighted average cost of HKD 6.90 per share, bringing total cash outflow for the transaction to HKD 0.99 million.

Following the buyback, the company’s outstanding share count (excluding treasury shares) declined marginally by 0.04 % to 322.24 million, while treasury shares increased to 1.73 million. Total issued shares remain unchanged at 323.97 million.

The repurchase forms part of the mandate approved on 26 June 2026, which authorises CF PharmTech to buy back up to 30.08 million shares. Cumulative repurchases under this mandate now stand at 337,800 shares, equivalent to 0.11 % of the company’s issued shares on the mandate date.

In line with Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 30 October 2026.